Familial cortical dysplasia caused by mutation in the mammalian target of rapamycin regulator NPRL3
dc.contributor.author | Sim, J. | |
dc.contributor.author | Scerri, T. | |
dc.contributor.author | Fanjul-Fernández, M. | |
dc.contributor.author | Riseley, J. | |
dc.contributor.author | Gillies, G. | |
dc.contributor.author | Pope, K. | |
dc.contributor.author | Van Roozendaal, H. | |
dc.contributor.author | Heng, Julian | |
dc.contributor.author | Mandelstam, S. | |
dc.contributor.author | McGillivray, G. | |
dc.contributor.author | Macgregor, D. | |
dc.contributor.author | Kannan, L. | |
dc.contributor.author | Maixner, W. | |
dc.contributor.author | Harvey, A. | |
dc.contributor.author | Amor, D. | |
dc.contributor.author | Delatycki, M. | |
dc.contributor.author | Crino, P. | |
dc.contributor.author | Bahlo, M. | |
dc.contributor.author | Lockhart, P. | |
dc.contributor.author | Leventer, R. | |
dc.date.accessioned | 2018-12-13T09:08:39Z | |
dc.date.available | 2018-12-13T09:08:39Z | |
dc.date.created | 2018-12-12T02:47:06Z | |
dc.date.issued | 2016 | |
dc.identifier.citation | Sim, J. and Scerri, T. and Fanjul-Fernández, M. and Riseley, J. and Gillies, G. and Pope, K. and Van Roozendaal, H. et al. 2016. Familial cortical dysplasia caused by mutation in the mammalian target of rapamycin regulator NPRL3. Annals of Neurology. 79 (1): pp. 132-137. | |
dc.identifier.uri | http://hdl.handle.net/20.500.11937/71048 | |
dc.identifier.doi | 10.1002/ana.24502 | |
dc.description.abstract |
© 2015 American Neurological Association. We describe first cousin sibling pairs with focal epilepsy, one of each pair having focal cortical dysplasia (FCD) IIa. Linkage analysis and whole-exome sequencing identified a heterozygous germline frameshift mutation in the gene encoding nitrogen permease regulator-like 3 (NPRL3). NPRL3 is a component of GAP Activity Towards Rags 1, a negative regulator of the mammalian target of rapamycin complex 1 signaling pathway. Immunostaining of resected brain tissue demonstrated mammalian target of rapamycin activation. Screening of 52 unrelated individuals with FCD identified 2 additional patients with FCDIIa and germline NPRL3 mutations. Similar to DEPDC5, NPRL3 mutations may be considered as causal variants in patients with FCD or magnetic resonance imaging-negative focal epilepsy. | |
dc.publisher | John Wiley and Son | |
dc.title | Familial cortical dysplasia caused by mutation in the mammalian target of rapamycin regulator NPRL3 | |
dc.type | Journal Article | |
dcterms.source.volume | 79 | |
dcterms.source.number | 1 | |
dcterms.source.startPage | 132 | |
dcterms.source.endPage | 137 | |
dcterms.source.issn | 0364-5134 | |
dcterms.source.title | Annals of Neurology | |
curtin.department | Health Sciences Research and Graduate Studies | |
curtin.accessStatus | Fulltext not available |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |